Source comparison
HGH vs. Ipamorelin | Comprehensive Comparison
Both hGH and ipamorelin have been shown to reliably increase hGH levels in study volunteers with functional pituitary glands. This effect can be assessed either directly by measuring the amount of serum GH following ipamorelin administration, or indirectly by
This comparison does not assign a generated winner or score.
- Both hGH and ipamorelin have been shown to reliably increase hGH levels in study volunteers with functional pituitary glands.
- This effect can be assessed either directly by measuring the amount of serum GH following ipamorelin administration, or indirectly by measuring the amount of insulin-like growth factor-1 (IGF-1) following hGH therapy. IGF-1 is the main anabolic mediator of growth hormone.
- Here are some of the most notable hGH effects, as reported by scientific studies:
- Recombinant hGH has been reported to upregulate the production of IGF-1 in GHD patients receiving daily physiological doses (2IU/m2 of body surface) of the medication. After four months of therapy, IGF-1 levels rose from the lower limit of the reference range (98mcg/l) to its upper limit (323mcg/l) [12].
- In a study on patients with HIV-associated muscle wasting, supraphysiological doses of hGH (0.1mg/kg of body weight) were reported to cause a significant increase in lean mass (+6.6lb) within three months of therapy. However, the therapy at this dosage also led to a high incidence of side effects such as joint pain (50% of patients) and swelling in the limbs (37% of patients) [13].
- Ipamorelin works by stimulating endogenous GH synthesis. Therefore, the peptide can upregulate GH levels only in subjects with functional pituitary glands. In these subjects, ipamorelin may even be capable of causing supraphysiological GH levels at high doses and may be safer than hGH at stimulating weight gain.
- A study in healthy volunteers reported that a single injection of ipamorelin, at a dose of 100mcg/kg of body weight, led to dramatically increased GH levels that reached up to 80mIU/l (about 26.6ng/ml). The researchers also reported similar GH peaks at lower doses (60mcg/kg) [11].
- Preclinical studies report that ipamorelin can increase weight gain in test animals by increasing GH levels and appetite. In a study in healthy mice, the peptide led to a 16.9% increase in body weight, compared to 27.5% for hGH therapy. Yet, it's important to note that hGH therapy was also associated with organomegaly. On the other hand, most weight gain in the ipamorelin group occurred within the first two weeks, and the peptide did not cause organomegaly [14].